Safety of Treatments for ADHD in Adults: Pairwise and Network Meta-Analyses

Chierrito de Oliveira, D; Guerrero de Sousa, P; Borges dos Reis, C; Tonin, FS; Maria Steimbach, L; Virtuoso, S; Fernandez-Llimos, F; Pontarolo, R; Cristina Conegero Sanches, A

Safety of Treatments for ADHD in Adults: Pairwise and Network Meta-Analyses

Chierrito de Oliveira, D Guerrero de Sousa, P Borges dos Reis, C Tonin, FS Maria Steimbach, L Virtuoso, S Fernandez-Llimos, F

Pontarolo, R Cristina Conegero Sanches, A

Permalink

Publication Type:: Journal Article
Citation:: Journal of Attention Disorders, 2019, 23 (2), pp. 111 - 120
Issue Date:: 2019-01-01

Closed Access

	Filename	Description	Size
	1087054717696773.pdf	Published Version	292.06 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Chierrito de Oliveira, D	en_US
dc.contributor.author	Guerrero de Sousa, P	en_US
dc.contributor.author	Borges dos Reis, C	en_US
dc.contributor.author	Tonin, FS	en_US
dc.contributor.author	Maria Steimbach, L	en_US
dc.contributor.author	Virtuoso, S	en_US
dc.contributor.author	Fernandez-Llimos, F https://orcid.org/0000-0002-8529-9595	en_US
dc.contributor.author	Pontarolo, R	en_US
dc.contributor.author	Cristina Conegero Sanches, A	en_US
dc.date.issued	2019-01-01	en_US
dc.identifier.citation	Journal of Attention Disorders, 2019, 23 (2), pp. 111 - 120	en_US
dc.identifier.issn	1087-0547	en_US
dc.identifier.uri	http://hdl.handle.net/10453/136331
dc.description.abstract	© The Author(s) 2017. Objective: The aim of the study was to analyze evidence comparing the profile of drugs used to treat ADHD in adult patients. Method: Systematic searches were conducted in electronic databases. Randomized, double-blind, parallel controlled trials that evaluated the safety of drugs in ADHD were included. The statistical analyses were conducted by pairwise meta-analyses and mixed treatment comparison (MTC). Results: Ten (n = 3006) trials were included in the analyses. We observed statistical differences for the following outcomes: decreased appetite between atomoxetine and placebo (odds ratio [OR] = 0.15, 95% credibility interval [CrI] = [0.05, 0.38]) and extended-release mixed amphetamine salts and placebo (OR = 0.06, 95% CrI = [0.00, 0.51]); insomnia between atomoxetine and placebo (OR = 0.48, 95% CrI = [0.27, 0.88]) and extended-release mixed amphetamine salts and placebo (OR = 0.23, 95% CrI = [0.06, 0.76]); sleepiness between atomoxetine and methylphenidate OROS (OR = 0.24, 95% CrI = [0.06, 0.97]); and decreased libido between atomoxetine and placebo (OR = 0.28, 95% CrI = [0.08, 0.90]). Conclusion: It was possible to generate evidence about the safety profile of different ADHD drugs.	en_US
dc.relation.ispartof	Journal of Attention Disorders	en_US
dc.relation.isbasedon	10.1177/1087054717696773	en_US
dc.subject.classification	Developmental & Child Psychology	en_US
dc.title	Safety of Treatments for ADHD in Adults: Pairwise and Network Meta-Analyses	en_US
dc.type	Journal Article
utslib.citation.volume	2	en_US
utslib.citation.volume	23	en_US
utslib.for	1701 Psychology	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
utslib.copyright.status	closed_access
pubs.issue	2	en_US
pubs.publication-status	Published	en_US
pubs.volume	23	en_US

Abstract:

© The Author(s) 2017. Objective: The aim of the study was to analyze evidence comparing the profile of drugs used to treat ADHD in adult patients. Method: Systematic searches were conducted in electronic databases. Randomized, double-blind, parallel controlled trials that evaluated the safety of drugs in ADHD were included. The statistical analyses were conducted by pairwise meta-analyses and mixed treatment comparison (MTC). Results: Ten (n = 3006) trials were included in the analyses. We observed statistical differences for the following outcomes: decreased appetite between atomoxetine and placebo (odds ratio [OR] = 0.15, 95% credibility interval [CrI] = [0.05, 0.38]) and extended-release mixed amphetamine salts and placebo (OR = 0.06, 95% CrI = [0.00, 0.51]); insomnia between atomoxetine and placebo (OR = 0.48, 95% CrI = [0.27, 0.88]) and extended-release mixed amphetamine salts and placebo (OR = 0.23, 95% CrI = [0.06, 0.76]); sleepiness between atomoxetine and methylphenidate OROS (OR = 0.24, 95% CrI = [0.06, 0.97]); and decreased libido between atomoxetine and placebo (OR = 0.28, 95% CrI = [0.08, 0.90]). Conclusion: It was possible to generate evidence about the safety profile of different ADHD drugs.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/136331